Stockreport
Incyte misses quarterly profit on weak sales of lead drug [Reuters]
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG In April, the company also announced it had entered into a definitive agreement to acquire Escient Pharmaceuticals, a clinical-stage company involved in the development of treatment of various skin diseases. Sales of Jakafi were down 1% to $571.8 million for the quarter, compared with analysts' expectations of $615.80 million, according to LSEG data. Chief Executive Officer Hervé Hoppenot said, "As anticipated, the revenue growth during the quarter was offset by an inventory drawdown for Jakafi and the typical first-quarter net pricing dynamics." Total re
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash? [Forbes][Forbes]
- Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress [Yahoo! Finance][Yahoo! Finance]
- Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress[Business Wire]
- Company News For May 14, 2024 [Yahoo! Finance][Yahoo! Finance]
- Stock market today: Asian shares mixed in muted trading after Wall Street barely budges [Yahoo! Finance Canada][Yahoo! Finance Canada]
- More
INCY
SEC Filings
SEC Filings
- 5/15/24 - Form SC
- 5/13/24 - Form SC
- 5/13/24 - Form SC
- INCY's page on the SEC website
- More